CpG island methylation status in the EpCAM promoter region and gene expression

Oncology Reports

Volumn 20, Issue 5, 2008, Pages 1061-1067

  Yu, Guolong ^a,b   Zhang, Xiangzhong ^c   Wang, Huaqiao ^a   Rui, Derong ^c   Yin, Aihua ^a   Qiu, Geng ^c   He, Yunshao ^c  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

5 Aza 2 deoxytidine; Bisulfate sequencing PCR; CpG island; Epithelial cell adhesion molecule; Methylation; Promoter

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE; CELL ADHESION MOLECULE; TACSTD1 PROTEIN, HUMAN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROMOTER REGION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; MOLECULAR GENETICS; NEOPLASM; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANTIGENS, NEOPLASM; BASE SEQUENCE; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MOLECULAR SEQUENCE DATA; NEOPLASMS; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 58149359348     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000110     Document Type: Article

References (35)

1. Linnenbach AJ, Seng BA, Wu S, et al: Retroposition in a family of carcinoma-associated antigen genes. Mol Cell Biol 13: 1507-1515, 1993.
2. Litvinov SV, Velders MP, Bakker HA, Fleuren GJ and Warnaar SO: Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol 125: 437-446, 1994.
3. Litvinov SV, Bakker HA, Gourevitch MM, Velders MP and Warnaar SO: Evidence for a role of the epithelial glycoprotein 40 (Ep-CAM) in epithelial cell-cell adhesion. Cell Adhes Commun 2: 417-428, 1994.
4. Balzar M, Winter MJ, de Boer CJ and Litvinov SV: The biology of the 17-1A antigen (Ep-CAM). J Mol Med 77: 699-712, 1999.
5. Szala S, Froehlich M, Scollon M, et al: Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2. Proc Natl Acad Sci USA 87: 3542-3546, 1990.
6. Simon B, Podolsky DK, Moldenhauer G, Isseibacher KJ, Gattoni-Celli S and Brand SJ: Epithelial glycoprotein is a member of a family of epithelial cell surface antigens homologous to nidogen, a matrix adhesion protein. Proc Natl Acad Sci USA 87: 2755-2759, 1990.
7. Strnad J, Hamilton AE, Beavers LS, et al: Molecular cloning and characterization of a human adenocarcinoma/epithelial cell surface antigen complementary DNA. Cancer Res 49: 314-317, 1989.
8. Calabrese G, Crescenzi C, Morizio E, Palka G, Guerra E and Alberti S: Assignment of TACSTD1 (alias TROP1, M4S1) to human chromosome 2p21 and refinement of mapping of TACSTD2 (alias TROP2, M1S1) to human chromosome 1p32 by in situ hybridization. Cytogenet Cell Genet 92: 164-165, 2001.
9. Ragnhammar P, Fagerberg J, Frodin JE, et al: Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma - long-lasting, complete remissions can be induced. Int J Cancer 53: 751-758, 1993.
10. Riethmuller G, Holz E, Schlimok G, et al: Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 16: 1788-1794, 1998.
11. Went PT, Lugli A, Meier S, et al: Frequent EpCam protein expression in human carcinomas. Hum Pathol 35: 122-128, 2004.
12. Spizzo G, Obrist P, Ensinger C, et al: Prognostic significance of Ep-CAM AND Her-2/neu overexpression in invasive breast cancer. Int J Cancer 98: 883-888, 2002.
13. Seligson DB, Pantuck AJ, Liu X, et al: Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma. Clin Cancer Res 10: 2659-2669, 2004.
14. Varga M, Obrist P, Schneeberger S, et al: Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin Cancer Res 10: 3131-3136, 2004.
15. Gires O, Eskofier S, Lang S, Zeidler R and Munz M: Cloning and characterisation of a 1.1 kb fragment of the carcinomaassociated epithelial cell adhesion molecule promoter. Anticancer Res 23: 3255-3261, 2003.
16. McLaughlin PM, Trzpis M, Kroesen BJ, et al: Use of the EGP-2/ Ep-CAM promoter for targeted expression of heterologous genes in carcinoma derived cell lines. Cancer Gene Ther 11: 603-612, 2004.
17. Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428, 2002.
18. Robertson KD: DNA methylation, methyltransferases, and cancer. Oncogene 20: 3139-3155, 2001.
19. Hanada M, Delia D, Aiello A, Stadtmauer E and Reed JC: bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 82: 1820-1828, 1993.
20. De Smet C, De Backer O, Faraoni I, et al: The activation of human gene MAGE-1 in tumor cells is correlated with genomewide demethylation. Proc Natl Acad Sci USA 93: 7149-7153, 1996.
21. Nakayama M, Wada M, Harada T, et al: Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias. Blood 92: 4296-4307, 1998.
22. Cho M, Uemura H, Kim SC, et al: Hypomethylation of the MN/CA9 promoter and upregulated MN/CA9 expression in human renal cell carcinoma. Br J Cancer 85: 563-567, 2001.
23. Rosty C, Ueki T, Argani P, et al: Overexpression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation. Am J Pathol 160: 45-50, 2002.
24. Herman JG: Hypermethylation of tumor suppressor genes in cancer. Semin Cancer Biol 9: 359-367, 2002.
25. Bird A: DNA methylation patterns and epigenetic memory. Genes Dev 16: 6-21, 2002.
26. Herman JG and Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054, 2003.
27. Muller PY, Janovjak H, Miserez AR and Dobbie Z: Processing of gene expression data generated by quantitative real-time RT-PCR. Biotechniques 32: 1372-1379, 2002.
28. Brandeis M, Frank D, Keshet I, et al: Sp1 elements protect a CpG island from de novo methylation. Nature 371: 435-438, 1994.
29. Macleod D, Charlton J, Mullins J and Bird AP: Sp1 sites in the mouse aprt gene promoter are required to prevent methylation of the CpG island. Genes Dev 8: 2282-2292, 1994.
30. Spizzo G, Gastl G, Obrist P, et al: Methylation status of the Ep-CAM promoter region in human breast cancer cell lines and breast cancer tissue. Cancer Lett 246: 253-261, 2007.
31. Tai KY, Shiah SG, Shieh YS, et al: DNA methylation and histone modification regulate silencing of epithelial cell adhesion molecule for tumor invasion and progression. Oncogene 26: 3989-3997, 2007.
32. El-Osta A and Wolffe AP: DNA methylation and histone deacetylation in the control of gene expression: basic biochemistry to human development and disease. Gene Expr 9: 63-75, 2000.
33. Bird A: The essentials of DNA methylation. Cell 70: 5-8, 1992.
34. Went P, Vasei M, Bubendorf L, et al: (Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 94: 128-135, 2006.
35. Turner R and Tjian R: Leucine repeats and an adjacent DNA binding domain mediate the formation of functional cFos-cJun heterodimers. Science 243: 1689-1694, 1989.